10x Genomics Announces Its Chromium Single Cell Gene Expression And Xenium In Situ Platforms Were Used In A Publication, Featured On The Cover Of Cancer Cell, Shedding Light On The Role Of Fibrotic Scars In Glioblastoma Treatment Recurrence
Shareholders in 10x Genomics (NASDAQ:TXG) Have Lost 87%, as Stock Drops 7.8% This Past Week
Torex Gold Resources Analyst Ratings
Stephens & Co. Reiterates Overweight on 10x Genomics, Maintains $30 Price Target
CCORF Maintains 10x Genomics(TXG.US) With Buy Rating, Maintains Target Price $32
CCORF analyst Kyle Mikson CFA maintains $10x Genomics(TXG.US)$ with a buy rating, and maintains the target price at $32.According to TipRanks data, the analyst has a success rate of 26.4% and a
10x Genomics Unveils Chromium Xo: A Low-Cost Instrument to Expand Access to High-Performance Single Cell Research